Evidence map›Paper›PMID 41761303›Full record

ArticleJournal of translational medicine2026

A bio-fortified whole tomato food supplement as potential dietary tool for the management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).

Pier Giorgio Natali, Luisa Imberti, Mauro Piantelli, Marco Minacori, Alessandra Sottini, Erica Gianazza, Cristina Banfi

Abstract read
In one paragraph

Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Pier Giorgio NataliMediterranean Task Force for Cancer Control (MTCC), via Pizzo Bernina, 14, 00141, Rome, Italy. natalipg2002@yahoo.it.ORCID 0000-0002-2843-3313
Luisa ImbertiSection of Microbiology, University of Brescia, P. le Spedali Civili, 1, Brescia, Italy.
Mauro PiantelliDepartment of Medicine and Aging Sciences, Center for Advanced Studies and Technology (CAST), G. D'Annunzio University, Via Luigi Polacchi, 11, 66100, Chieti, Italy.
Marco MinacoriDepartment of Bioscience and Agro-Food and Environmental Technology, University of Teramo, Campus "Aurelio Saliceti", Via R. Balzarini, 1, 64100, Teramo, Italy.
Alessandra SottiniHighly Specialized Laboratory, Service Department, ASST Spedali Civili of Brescia, P.le Spedali Civili, 1, 25123, Brescia, Italy.
Erica GianazzaCentro Cardiologico Monzino IRCCS, Unit of Functional Proteomics, Metabolomics, and Network Analysis, Via Privata Carlo Parea, 4, 20138, Milan, Italy.
Cristina BanfiCentro Cardiologico Monzino IRCCS, Unit of Functional Proteomics, Metabolomics, and Network Analysis, Via Privata Carlo Parea, 4, 20138, Milan, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWestern diets, rich in refined fats and carbohydrates, are recognized as a major player in hepatic lipid accumulation in adults and youngsters, leading to the growing prevalence of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), formerly known as non-alcoholic fatty liver disease, the gate to cirrhosis and cancer. Due to the lack of approved therapies, antioxidant-rich dietary regimens targeting MASLD relevant pathologic pathways may be of more immediate translational impact. As tomatoes are a major globally accessible source of antioxidant/inflammatory nutrients, we have investigated whether a novel whole tomato-based food supplement (WTFS), possessing an effective antioxidant activity and hindering multiple metabolic pathways, can interfere with mechanisms fostering MASLD progression.

methodsLipidomic and proteomic analyses were performed in the HepG2 liver human cell line treated with WTSF.

resultsWTFS induces a marked reduction in triglycerides and cholesterol ester content, a decrease in the relative levels of diacylglycerols, lysophosphatidylcholine, lysophosphatidylethanolamines, phosphatidylethanolamines, and lower expression of transforming growth factor-α, tumor necrosis factor-like weak inducer of apoptosis (TWEAK), and Fms-related tyrosine kinase 3 ligand (FLT3LG), signaling relevant to MASLD progression.

conclusionsWTFS may represent a potential candidate for clinical trials in supplementing antioxidant-rich dietary regimens such as the healthy but hard-to-follow Mediterranean diet, the presently first-line preventive and therapeutic nutritional regimen for MASLD.

Indexed as

Dietary SupplementsFatty LiverMetabolic DiseasesNon-alcoholic Fatty Liver DiseaseSolanum lycopersicumAntioxidantsHep G2 CellsHumansAntioxidantsAntioxidantsFunctional foodsLipidsMetabolic Dysfunction-Associated Steatotic Liver DiseaseTomato

Identifiers

PMID41761303
PMCPMC13040914

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.